Rhythm Pharmaceuticals (RYTM)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.29 (+0.50%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Rhythm Pharmaceuticals (RYTM)
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.

Key Insights

Critical company metrics and information
  • Share Price

    $57.60
  • Market Cap

    $3.54 Billion
  • Total Outstanding Shares

    61.46 Million Shares
  • Total Employees

    226
  • Dividend

    No dividend
  • IPO Date

    October 5, 2017
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    http://www.rhythmtx.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities, Continuing$-46.69 Million
Net Cash Flow From Operating Activities$-124.42 Million
Net Cash Flow, Continuing$-15.77 Million
Net Cash Flow From Investing Activities$-46.69 Million
Net Cash Flow From Financing Activities, Continuing$155.34 Million
Net Cash Flow From Operating Activities, Continuing$-124.42 Million
Net Cash Flow From Financing Activities$155.34 Million
Net Cash Flow$-15.77 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Operating Expenses$365.23 Million
Net Income/Loss Available To Common Stockholders, Basic$-261.57 Million
Income/Loss From Continuing Operations After Tax$-258.94 Million
Basic Average Shares$182.89 Million
Basic Earnings Per Share$-4.33
Costs And Expenses$378.05 Million
Selling, General, and Administrative Expenses$138.55 Million
Preferred Stock Dividends And Other Adjustments$2.63 Million
Net Income/Loss Attributable To Parent$-258.94 Million
Operating Income/Loss$-265.51 Million
Diluted Earnings Per Share$-4.32
Gross Profit$99.72 Million
Net Income/Loss$-258.94 Million
Diluted Average Shares$122.32 Million
Research and Development$226.68 Million
Revenues$112.53 Million
Cost Of Revenue$12.81 Million
Income/Loss From Continuing Operations Before Tax$-258.31 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Benefits Costs and Expenses$370.81 Million
Income Tax Expense/Benefit$631,000.00
Nonoperating Income/Loss$7.24 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$2.63 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Equity Attributable To Noncontrolling Interest$0.00
Equity Attributable To Parent$11.21 Million
Other Current Assets$28.06 Million
Assets$363.57 Million
Temporary Equity Attributable To Parent$141.48 Million
Other Non-current Assets$22.43 Million
Current Assets$340.34 Million
Noncurrent Liabilities$113.27 Million
Temporary Equity$141.48 Million
Inventory$13.89 Million
Noncurrent Assets$23.23 Million
Liabilities And Equity$363.57 Million
Cash$298.39 Million
Fixed Assets$801,000.00
Other Current Liabilities$92.72 Million
Equity$11.21 Million
Accounts Payable$4.89 Million
Current Liabilities$97.61 Million
Liabilities$210.88 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.